VARIABLES AFFECTING PRICING OF ORPHAN DRUGS: THE ITALIAN CASE

被引：0
|
作者：
Jommi, C. [1 ]
Listorti, E. [1 ]
Villa, F. [2 ]
Ghislandi, S. [3 ]
Genazzani, A. [4 ]
Cangini, A. [5 ]
Trotta, F. [5 ]
机构：
[1] Bocconi Univ, SDA Bocconi Sch Management, Milan, MI, Italy
[2] Astrazeneca, Milan, Italy
[3] Bocconi Univ, Milan, Italy
[4] A Avogadro Univ, Novara, Italy
[5] AIFA Natl Med Agcy, Rome, Italy
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSC207
引用
收藏
页码：S148 / S148
页数：1
相关论文
共 50 条
  • [21] Is orphan drug pricing blowing a bubble? The unique situation of orphan drugs and why high prices will likely persist
    Michaud, John-Paul
    Modi, Robin
    Phillips, M. Ian
    EXPERT OPINION ON ORPHAN DRUGS, 2013, 1 (09): : 675 - 679
  • [22] Orphan drugs policies: a suitable case for treatment
    Drummond, Michael
    Towse, Adrian
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2014, 15 (04): : 335 - 340
  • [23] Pricing and Reimbursement Pathways of New Orphan Drugs in South Korea: A Longitudinal Comparison
    Lee, Jong Hyuk
    HEALTHCARE, 2021, 9 (03)
  • [24] Extraordinary Pricing of Orphan Drugs: Is it a Socially Responsible Strategy for the US Pharmaceutical Industry?
    Hemphill, Thomas A.
    JOURNAL OF BUSINESS ETHICS, 2010, 94 (02) : 225 - 242
  • [25] ORPHAN DRUGS FACE TOUGHER SCRUTINY IN SECURING FAVORABLE PRICING AND MARKET ACCESS
    Grosvenor, A.
    Saraf, S.
    Jones, K.
    VALUE IN HEALTH, 2011, 14 (03) : A22 - A22
  • [26] FAIR PRICING OF ORPHAN DRUGS IN RELATION TO ADDITIONAL HEALTH GAINS AND DISEASE PREVALENCE
    Zelei, T.
    Csanadi, M.
    VALUE IN HEALTH, 2017, 20 (09) : A570 - A571
  • [27] IS ORPHAN DESIGNATION A DRIVER OF ORPHAN DRUG PRICING?
    Degrassat-Theas, A.
    Paubel, P.
    de Curzon, Parent O.
    Berard, F.
    Poisson, N.
    Le Pen, C.
    Sinegre, M.
    VALUE IN HEALTH, 2012, 15 (07) : A302 - A302
  • [28] Orphan drugs and orphan diseases
    Campos-Castelló, J
    REVISTA DE NEUROLOGIA, 2001, 33 (03) : 216 - 220
  • [29] ORPHAN DRUGS TO TREATING RARE DISEASES: THE ITALIAN WAY FOR AN EARLY ACCESS
    Prada, M.
    Sansone, C.
    Bisagni, D.
    Mantovani, M.
    VALUE IN HEALTH, 2017, 20 (05) : A233 - A234
  • [30] Role of healthcare databases and registries for surveillance of orphan drugs in the real-world setting: the Italian case study
    Crisafulli, Salvatore
    Sultana, Janet
    Ingrasciotta, Ylenia
    Addis, Antonio
    Cananzi, Pasquale
    Cavagna, Lorenzo
    Conter, Valentino
    D'Angelo, Gabriella
    Ferrajolo, Carmen
    Mantovani, Lorenzo
    Pastorello, Maurizio
    Scondotto, Salvatore
    Trifiro, Gianluca
    EXPERT OPINION ON DRUG SAFETY, 2019, 18 (06) : 497 - 509
12345